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Pancreatic cancer is a challenging cancer with a high mortality rate and a 5-year
survival rate between 2% to 9%. The role of biomarkers is crucial in cancer prognosis,
diagnosis, and predicting the possible responses to a specific therapy. The Discovery and
development of various types of biomarkers have been studied intensively in the hope of
determining the best treatment approaches, better management, and possibly cure of this
deadly cancer. However, metastasis, responsible for about 90% of the deaths from cancer,
is still poorly understood. A few research that have investigated the expression of a
particular biomarker or a panel of biomarkers in the primary and secondary (metastatic)
tumor demonstrates that the expression of different biomarkers in the primary and
secondary tumor sites is not necessarily the same, even though the primary and metastatic
tumor cells are originated from the same organ. In this project, we aim to design a classifier
to distinguish between primary and secondary tumor cells based on their uptake of different
biomarkers, using immunofluorescence whole slide imaging. For this purpose, we first
register consecutive images of the same slide together to be able to locate multiple
biomarkers that belong to a cell and later we design our classifier based on vectors that
show the presence or absence of multiple antibodies in addition to the amount of that
antibody in a tumor cell.
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Chapter 1

Introduction
1.1.

Pancreatic cancer
Pancreatic cancer initiates in the pancreas, a body organ located behind the stomach

and next to the small intestine, Fig 1. This organ, which consists of three parts: head, body,
and tail, has two kinds of cells: endocrine cells and exocrine cells. Endocrine cells secrete
hormones such as insulin to regulate blood sugar. Exocrine cells release enzymes to help
with food digestion. The different kinds of pancreatic cancer are divided into two main
groups; exocrine tumors and neuroendocrine tumors.
Pancreatic Ductal Adenocarcinoma (PDAC), an exocrine tumor, is one of the most
common types of pancreatic cancer that occurs in the pancreatic ducts. Due to the location
of the pancreas in the belly, pancreatic tumors are not usually felt by pressing the belly.
The symptoms appear when cancer has spread to other body organs, which explains why
pancreatic cancer is rarely diagnosed at the stage when it could be cured [1].
Despite all advances in cancer treatment, this malignancy still remains one of the
deadliest cancers. Its 5-year survival rate ranges from 2% to 9 % in the United States [2],
and approximately 7% of all cancer deaths come from this type of cancer [3]. Although the
main causes of this type of cancer are not yet identified, factors such as smoking, obesity,
and specific gene mutations such as KRAS mutation may affect the chance of getting this
disease.
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Fig 1. Location of the pancreas in the body (Image courtesy Mayo Clinic)

Although this challenging cancer is not curable and has an abysmal survival rate,
fast-paced cancer studies in recent years have deepened our understanding of the biology
of pancreatic cancer which in turn has affected the management of this cancer in different
aspects such as early detection, medical therapy, and drug development. According to the
World Health Organization (WHO), a biomarker is defined as “any substance, structure,
or process that can be measured in the body or its products and influence or predict the
incidence of outcome or disease.”[4] . The discovery and development of minimally
invasive robust biomarkers with high sensitivity and specificity is one of the most
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important steps for moving toward personalized medicine and avoid unnecessary
treatments with the high cost and adverse side effects on the patients [5]. Also, different
imaging modalities in combination with biomarkers have provided ample opportunities for
improving cancer detection and treatment and have made designing patient-specific
therapies for different types of cancer more feasible while the biomarker assessment
indicates the presence of any disease, imaging techniques can facilitate this task. Also, they
can be harnessed to locate the tumor and identify the aggressiveness of the tumor [6].Whole
slide imaging is one of the most recent imaging modalities with novel technology, which
has several clinical and non-clinical applications that can be used to test for the presence
of any cancerous antibody.

1.2.

Problem statement and Organization of this Thesis
The ultimate goal of this project from the outset was to develop an algorithm that

would be able to classify pancreatic cancer cells into primary or metastatic (secondary)
categories based on the differential uptake of antibodies as a tumor marker. Sets of
antibodies with fluorescent labels are applied to the tissue and imaged. The tissue is
washed between applications. Since a glass slide is manually located inside the tray of a
whole slide image scanner, each rescan of the tissue results in an image with the tissue at
a slightly different orientation and therefore different coordinates for collocated pixels,
consequently, coordination of the points will change. This problem is resolved by
registering the consecutive images of a slide together. In order to analyze the presence or
absence of all antibodies in consecutive images of a tissue, prior to ascertaining which cells
are taking up which antibodies, the different scans must be registered. Once the scans are
registered, the location of the cells taking up different antibodies can be specified and used
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in addition to each antibody’s expression associated with the cell. Together, these form the
components of a feature vector, all vectors create a big matrix which will be the input to
machine learning algorithms developed for classifying the cells. In this research, after an
introduction about pancreatic cancer in chapter one, we will give an overview of the
problem and explain how we will be dealing with this problem. In chapter two, we will
describe the digital pathology or whole slide imaging system, its applications, benefits, and
drawbacks. Later we broadly talk about biomarkers and tumor environment in pancreatic
cancer and explain how the use of biomarkers is important in the prognosis, diagnosis, and
prediction of different therapeutic approaches in pancreatic cancer and how intensive
research in this area is bringing hope for better management and even cure of this deadly
disease.
In chapter 3, we will be working with thumbnail brightfield and
immunofluorescence images. First, we register two consecutive brightfield thumbnail
images based on finding fiducial markers, and in the second part we will be registering
immunofluorescence images of the tissue samples.
In the evaluation of differences between normal and cancer cells - the details of
which are outside the scope of this project - usually morphology differences are analyzed.
Cancerous cells are different from normal cells in both shape and size. Figure 2 shows
some of the morphological differences between normal and cancerous cells. These
differences give the opportunity to design a classifier based on a single or a panel of
features including area, axes lengths, eccentricity, perimeter, circularity, and other
morphological characteristics. Most of the classifiers are designed based on normal versus
cancerous cells. However, in chapter 4, we implement two types of classifiers to investigate
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the differences between primary tumor and metastatic tumor cells; The first type is a
morphology-based classifier to analyze if primary tumor and metastatic tumor cells are
distinguishable morphologically. Finally, the second type of the classifier is designed to
assess how biomarker uptakes of primary tumor cells differ from their metastatic tumor
counterparts.

Fig 2. Normal cells versus cancer cells morphological characteristics [7]

The proposal of this project was based on immunohistochemical brightfield whole
slide images of pancreatic cancer tissues, however, we adjusted the research to the data sets
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that we received. Those data sets were received sequentially over the course of this project.
First, we found the fiducial markers inside the thumbnail images of a whole slide image
and registered two thumbnail images together based on these markers. Later, we received
two non-consecutive large brightfield whole slide images, and we started to work on those.
Shortly after, we received several small size brightfield images in different proprietary
formats and worked to change the format into .tiff or .jpeg to be able to process them. We
experienced a loss of information while converting to .jpeg or .tiff, and this is unacceptable
for the accuracy standards of pathology. Finally, we received immunofluorescence whole
slide images in small sizes (1017 x 1920 pixels) of primary and metastatic tumors. Only
for two patients did we have both primary and metastatic information. The images for the
remaining patients are either primary or metastatic without any ground truth. The public
datasets are mostly brightfield images of different types of cancer, and our aim was to
classify pancreatic cancer cells based on either morphology characteristics or uptaking
antibodies in immunofluorescence whole slide images. Besides, pancreatic cancer is
difficult for pathologists because “acini are cut obliquely, making it difficult to discern
their characteristics shape” [8], therefore images of other types of cancer are an insufficient
substitute for helping solve the challenge of pancreatic cancer.
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Chapter 2

Background
Before we start describing methods of registration of immunofluorescence whole
slide imaging and apply them to see the results of the registration and to locate multiple
biomarkers in chapter 3 and later classification of primary versus metastatic cancer cells in
pancreatic cancer in chapter 4, we introduce the whole slide imaging system (WSI), the
notion of biomarker and tumor microenvironment in this chapter. Also, based on reviewing
the existing literature we provide the background behind these concepts, explain how tumor
environment contributes in tumor progression and metastasis, discuss potential biological
markers in pancreatic cancer and how they can be promising in prognosis, diagnosis or
prediction of responses to different therapeutic approaches.

The quality of the microscope was enhanced since 1850, which paved the way for
the first pathology practices to start. Since that time, pathologists have been using the
traditional microscope as the gold standard for the diagnosis of cancer and other diseases.
Nevertheless, advances in digital imaging and image processing have opened a window to
move from traditional microscopy to virtual microscopy [9]. Figure 3 presents the
evolution of pathology over time.
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Fig 3. The evolution of pathology over time [10]

Wetzel and Gilbertson developed the first high-resolution whole-slide imaging
(WSI) system in 1999 [11]. In digital pathology, or Whole slide imaging, the glass slides
are scanned by a high-resolution scanning device under brightfield or fluorescent
conditions, and a high-resolution digital image of the entire microscope slide is created
[12]. The total scan time of a glass slide is less than one minute, with a resolution
comparable to seeing glass slides under a traditional microscope. Scanning can occur at
different magnifications. However, 20X magnification is acceptable for routine image
analysis. The digitization process includes scanning, storage, editing, and display. Each
whole slide imaging system consists of these components: light source, slide stage,
objective lenses, and a high-resolution camera [12]. In brightfield microscopy, which is the
most common type of microscopy, the light passing by the specimen is collected by the
objective lens beneath the specimen [13]. In fluorescent microscopy, specific structures in
the sample are labeled with fluorescent dyes named fluorophores. Only a few things in the
tissue sample are labeled with these fluorophores and therefore light up. This enables
practitioners to only see and focus on particular structures or objects instead of everything
on the entire slide [14].
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Between brightfield and immunofluorescence microscopy, which are both
molecular examinations of a microscope slide to detect specific proteins within the tissue,
brightfield is the most popular and preferred method for cancer diagnosis by pathologists.
However, there is an increasing demand for utilizing immunofluorescence in multiplex
biomarker detection because it can detect more than one biomarker per slide. Its
counterpart, brightfield microscopy, is performed to detect only a single biomarker per
slide. This might disrupt the tissue since it is being dyed and washed out several times [15].
In addition to its ability to detect multiple biomarkers, one of the most important
advantages of using fluorescence microscopy is that intensity is linear with the amount of
proteins. However, since low abundance proteins have weak signals, it is hard sometimes
to pull out these signals from underneath the bright signals [16]. Fig 4 represents a whole
slide image sample.
In digital pathology all the information, including slides and data can be examined,
managed, and shared in a digital environment. Whole Slide Imaging (WSI) increases the
workflow efficiency, offers decision support tools, and creates a connected team
environment that allows for the sharing of slides, team annotations, and markups remotely.
Also, Whole Slide Imaging could lead to considerable enhancement in translational
research and computer-aided diagnosis (CAD). Also, digitization gives the ability to
measure multiple areas of interest, evaluate several different viewing angles, views with
more accuracy, and gain new and better insights from analyzing a massive number of
images. All of this makes training, remote consultation, and clinical review easier [17].
Despite all the benefits of WSI, the high cost of scanners along with the need for a
huge amount of storage for the digital files are some of its drawbacks. In addition to these
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issues, there is also the challenge of the rate of pathologists who are familiar with this
technology being low at this point in time [18].

Fig 4. Omnyx whole slide imaging scanner and viewer [18]

For the first time in 2017, the United States food and drug administration (FDA)
approved the first commercial whole slide imaging (WSI) system, allowing the Philips
IntelliSite Pathology Solution (PIPS) which reviews and interprets digital surgical
pathology slides which have been prepared from biopsied tissue to enter the marketplace
[19].
After the increased interest in the most recent imaging modality, whole slide
imaging, for diagnostic, educational, and research purposes, one crucial question emerged.
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Researchers and practitioners continue to wonder if whole slide imaging is as accurate as
the optical microscopy that uses conventional glass slides. This led to a broad range of
research related to clinical validation and standardization of this kind of imaging.
In several studies about surgical pathology - the analysis of a removed tissue from
a living patient during surgery for diagnosis and treatment plan - WSI and traditional light
microscopy have been compared. These studies show that WSI is not inferior to light
microscopy, with one important caveat: WSI should be used for diagnosis purposes only
when the pathologists are formally trained on the equipment. WSI has also been compared
to traditional glass slides in the realm of primary diagnosis in anatomic pathology. It is
likewise non-inferior to its long-established counterpart in this dimension either [20]. A
meta-analysis, comprehensive literature search, among several publications from 2013 to
2019, which in total examined 10410 histology samples, demonstrated that there was a
98.3 % concordance between digital pathology (DP) and light microscopy (LM).
Therefore, there is an equivalency between DP and LM in routine diagnosis. Although the
discrepancies should be studied deeply before this emerging technology will take over
permanently [21]. The College of American Pathologists states that each laboratory that
works with whole slide systems, should conduct its own validation studies to be able to use
digital pathology for diagnostic purposes [22].

Research in cancer biology shows that the progression of cancer is not solely related
to changes in the tumor cells, as changes in the tumor microenvironment play a critical role
in tumor development and progression [23]. There are multiple exchanges between
cancerous cells and their neighboring microenvironment, and for understanding the
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initiation, development, and progression of cancers a comprehensive analysis of tumor
microenvironment to understand how it affects tumor growth and metastasis is essential.
its mutual are highly dependent on interactions between the cancerous and nonmalignant
cells in the tumor microenvironment [24-25].

The concept of tumor microenvironment (TME) dates back to 1889 when Stephen
Paget after examining the data of 735 women with breast cancer and noticed that metastasis
did not happen by chance, in fact for cancer cells (the seed) to metastasize a favorable
microenvironment

(the soil) is needed [26]. Tumor microenvironment is not only

important in metastasis but also the dynamic interactions of cancer cells with cellular and
acellular components of tumor microenvironment affects tumor growth and progression.

Pancreatic cancer is one of the most dangerous types of cancers with a high
mortality rate and a dismal prognosis. Most patients are diagnosed at the stage when the
tumor is locally advanced or has metastasized to other organs and therefore is not
resectable. The close incidence rate and mortality rate of this malignancy has fueled the
research to look deeply beyond the cancer cells and to further investigate the tumor
microenvironment and its vital role in cancer progression to find novel therapeutic
approaches for the treatment of pancreatic cancer.

The pancreatic cancer microenvironment is made up of cancer cells, tumor stromal
cells, immune cells like macrophages and extracellular components. The components that
are responsible for the progression of this malignancy are mainly regulatory T cells (Tregs),
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tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSCs) and
pancreatic stellate cells (PSC) [25],[27].
Recent studies show that the tumor microenvironment of pancreatic cancer,
including cancer-associated fibroblasts such as stellate cells, extracellular matrix, different
kinds of immune cells, and cytokines released by these cells, participates in the control of
proliferation, invasion, and metastasis, chemoresistance and immunotherapy of pancreatic
cancer by close interactions with cancer cells [27]; The dynamic interaction between tumor
cells and their surrounding tissue favors the survival of the cancerous cells in such a way
that the cancer cells divide and grow out of control following oncogenic mutations and
therefore elude anti-tumor immunity, while the tumor environment of pancreatic cancer
ductal adenocarcinoma can impact local immune response [25], [27].

There are two major characteristics of the pancreatic cancer microenvironment:
dense desmoplastic reaction which is referred to suffusive growth of condensed fibrous
tissue around the tumor, existing in both primary and metastatic tumors and extensive
immunosuppression; Dense fibrous tissue prevents the infiltration of immune cells in the
tumor tissue, making the tumor tissue escape from the surveillance of the immune system.
The desmoplasia builds a barrier around the tumor cells and therefore creates a
hypoxic microenvironment in which prevents the proper formation of blood vessels and
limits the exposure to chemotherapy and in consequence leads to poor immune cell
infiltration. In such a hypoxic environment, the oxygen consumption is increased, and
oxygen supply is compromised. Also, immunosuppressive molecules and cells by changing
the balance of immune effector cells create a unique immunosuppressive environment that
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facilitates cancer cell proliferation, the evasion of immune surveillance via the direct
inhibition of anti-tumor immunity or the induction of immunosuppressive cell proliferation
and metastasis [28]–[32].
Such an environment with these characteristics makes pancreatic cancer resistant
to different kinds of therapy such as chemotherapy, radiation therapy and immunotherapy
and this, in turn, promotes metastasis [28] ,[33]. Therefore, novel approaches to understand
how different components of the pancreatic cancer microenvironment contributes to cancer
progression and metastasis provide better insight to develop more effective treatments. For
instance, an important question to be investigated is whether the tumor microenvironment
characteristics in primary organ differ from the secondary organ when the tumor is
metastasized [31]. Up to date, several approaches and methods to treat pancreatic cancer
have failed or had unsatisfactory results Immunotherapy has improved cancer treatment
significantly in several malignancies; however, pancreatic cancer due to its unique complex
microenvironment remains unresponsive to conventional immunotherapies. However,
advances in several fields such as biology, genetic and immunology with emerging tools
like immunophenotyping, fluorescence multiplex imaging will facilitate deep
understanding of the tumor microenvironment and successful personalized therapies
hopefully in the near future [30-31], [34].

The role of biomarkers is crucial in cancer screening, prognosis, diagnosis, and
determining the best treatment approaches. Understanding the relationship between
biomarkers and their clinical results is of great significance not only to increase treatment
options for all diseases but also to understand the normal status of the human body. Several
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types of research have been performed since 1980 to examine the use of biomarkers in
extremely important diseases such as cancer, and the FDA has continued to promote the
use of biomarkers in clinical studies. However, biomarker-driven research has not been
easy due to a variety of factors: the relatively low number of patients or healthy individuals
that can be tested, the lack of assessment of the practicality of a proposed method, the
selection of an early-stage group of patients, the healthy control groups, and the nonspecificity of molecular markers.
Cancer biomarkers are classified into three groups; prognostic biomarkers that can
provide valuable information to patients and assist clinicians in adjusting their treatment
strategies according to the aggressiveness of the disease, diagnostic biomarkers that refers
to those markers assisting with the early detection of cancer and potentially curable stage
and predicting biomarkers that can help to predict how a patient might respond to treatment
and how to select different treatment protocols based on a biological rationale in the very
early stages of cancer that have the potential to improve patient survival rates [35]–[38].

In pancreatic cancer, one of the major challenges in biomarker development is
obtaining tumor tissue samples of adequate quality for analysis. Initial diagnosis of this
cancer is usually performed with fine needle aspiration (FNA), most commonly by
endoscopic ultrasound, and therefore fair tissue procurement is difficult to obtain. Taking
these biopsies is expensive, uncomfortable, and might lead to clinical complications.
These data highlight the need for biomarkers that are highly specific and easily
measurable by inexpensive sensitive techniques so that could improve the diagnosis and
accuracy of staging at the time of disease presentation to better inform first-line therapy
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[38], In addition, due to the low incidence of pancreatic cancer in the population,
stratification of the patients should be that accurate so that only those patients who truly
need that, continue to undergo further examinations by invasive and expensive modalities.
Therefore, minimally invasive modalities involving biomarkers and imaging techniques
that would facilitate the early detection of pancreatic cancer are highly needed [39]- [40].
This complex biology and heterogeneity of cancer makes it hard to diagnose and
treat effectively. Studies to develop novel potential biomarkers for diagnostic, predictive,
and prognostic purposes have been an area of extensive research lately with the hope of
finding effective management for this challenging cancer; however, none of them were
used in clinical trials [41]-[42]. Serum carbohydrate antigen (CA) 19-9 was discovered in
1979 [43], and it is the most validated diagnostic marker in pancreatic cancer with
sensitivity and specificity of 79-81% and 82-90%, respectively, but it is not useful in
screening due to its low sensitivity and specificity. Several other carbohydrate antigens
such as CA 50, CA-125, etc., have also been investigated, but studies demonstrate that they
are overall less sensitive than CA19-9 [44].
Among strategies to find predictive, prognostic, and diagnostic biomarkers for
pancreatic cancer liquid-based biopsies to detect circulating tumor cells (CTCs),
circulating free DNA (cfDNA), and extracellular vesicles (EVs) are promising markers for
early detection and diagnosis of PC [45]. These biomarkers, along with methylated DNA
and exosomes, can classify the patients with pancreatic cancer adenocarcinoma and predict
their sensitivity to the therapeutic methods [39]. Several studies show that exosomes
correlate with pancreatic cancer progression and metastasis, and due to the possibility of
detecting exosomes in different body fluids, they are considered as suitable potential

17

biomarkers in PC [46] Circular EV- based biomarkers are highly sensitive with high
positive predictive value and low false positive value and offer an excellent opportunity
for screening of individuals in pancreatic cancer [45]. Also, miRNA is another biomarker
that has gained attention lately to be used as a marker for early detection of PC. For
pancreatic cancer mass screening, affordable, convenient, and efficient testing with high
sensitivity and specificity close to 100 % that can be utilized effectively for all the
population is required [36].

Metastasis is responsible for the majority of cancer deaths; however, this phase of
cancer has remained poorly understood. Most of the literature deals with differentiating
between cancer versus normal situation in an organ [47]. A few studies have assessed the
expression of particular biomarkers in primary versus metastatic tumors in select types of
cancer. Stefanovic et al.[48] talk about how biomarkers change between primary and
metastatic tumors, and how the accurate assessment of biomarker conversion between
primary versus metastatic can minimize overtreatment for metastatic tumors. In [49]
Bhullar et al show that some biomarkers are highly concordant between colorectal cancer
and metastatic colorectal cancer, therefore a molecular examination of either a primary
tumor or its corresponding metastatic site is enough for designing the individual treatment.
Gomez-Roca and his colleagues [50] examined 49 patients to see if the expression of a
group of biomarkers - epidermal growth factor receptor (EGFR), vascular endothelial
growth factor receptor, Ki-67, and excision repair cross-complementing (ERCC1) - were
concordant in non-small cell lung cancer and its metastatic site. They demonstrated that
the expression of the evaluated biomarkers is discordant between a primary tumor and its
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corresponding metastatic site in 33 percent of cases. In only 18 percent of the tested
population, the expression of the biomarkers is the same in both primary and metastatic.
Ansari et al. [51]examined 17 cases of primary PDAC and their lymph node metastases to
study the expression of Mucin 4 (MUC4) antibody, which is a proposed role in pancreatic
cancer progression during the cancer metastasis by comparing its expression in primary
versus metastatic pancreatic ductal adenocarcinoma. They noticed that MUC4 was
expressed in both primary and secondary tumor with concordance of 82 %.
Therefore, based on the primary tumor, one cannot provide a suitable treatment
plan, and based on what we see in the literature, much more research are necessary to
evaluate the relationship between primary and metastatic biomarkers; their expression
pattern, the amount of expression and the presence or absence of any antibody in both
primary and metastatic tumor.
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Chapter 3

Image Registration

In image processing, Image registration is the task of aligning two images that are
taken from different viewpoints, different modalities or different time instances, involving
the transform of one of the two images such that at the end they will be in one coordinate
system. For this purpose, one image is used as the reference and the other one as the source
image. A geometrical transformation which is a mathematical mapping from points in one
image to the corresponding points in another image is calculated based on these two images
to be applied to the source image so that these two images align with each other. In
pathology, extracting information from different images of the same slide is done by
pathologist looking at them one at the time and this is significantly time consuming. The
assessment of expression of multiple biomarkers in a single view is possible only when the
consecutive images of a slide are aligned [52].
In this chapter, we will first register brightfield thumbnail whole slide images
together using the location of fiducial markers which are artificially added landmarks to a
slide. For this purpose, first, we need to detect the hashmarks in the images and later
register the two images together. Later, we will register immunofluorescence whole slide
images using corresponding features in both the reference image and the source image.
Feature-based registration techniques extract naturally occurring features from the images
rather than relying on the artificial landmarks.
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Methods of image registration could be divided based on different criteria. One of
the criteria is the nature of transformation [53]. Based on the Geometrical transformation
the image registration is divided to 4 types as follows. In rigid image registration only
rotations and translations are used in the transformation.
1.
2.
3.
4.

Rigid
Affine
Projective
Curved

3.1. Registration using Fiducial Markers
Since a glass slide is manually located inside the tray of a whole slide image
scanner, each scan might result in an image with a slightly different [0 0] coordination,
consequently coordination of the points will change and this problem will be resolved by
registering the consecutive images of a slide together.
A landmark is a recognizable feature that can be found in an image and can be used
to match two images in the thumbnail images, fiducial markers are suitable choices to be
used in image registration. For this purpose, first these markers should be detected and
segmented in both images automatically. Figure 5 shows a sample of the thumbnail
immunohistochemistry image that we use for detecting hash marks. As are seen the hash
marks here are in the shape of plus signs.
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Figure 5. Thumbnail immunohistochemistry image sample

The first method to detect fiducial markers starts with dividing the true color (RGB)
thumbnail image to two halves and only the top half is kept for object detection purposes,
because in this image the only thing that is needed for object detection and segmentation
is the hash mark(s) signs. Then the top half RGB image is converted to grayscale and then
to binary simply using Otsu thresholding method (Figure 5). As it can be observed, the
white objects in the background are easily discernable, so these objects are labeled and then
the properties of objects such as area, perimeter and etc. are calculated, then the boundaries
for target objects(blobs) are plotted. This also gives the coordinates of the hashmarks.
Finally, the detected hashmarks are imaged. Fig 6-9 and 10-11 present the results of the
mentioned steps for finding hashmarks inside the original and rotated images respectively.
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Figure 6. Binary image of the thumbnail image

Figure 7. Coordinates of Hash mark number 1

Figure 8. Coordinates of Hashmark number 2
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Figure 9. One of the hash marks as an image

Figure 10. Rotated image(left), Resulted cropped binary image(right)
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Figure 11. First and second hash mark boundaries and images

The second method for finding hash marks inside of the rotated image is template
matching. Template matching is a measure of similarity between a predefined template and
a reference image. Templates are usually used to identify small simple objects in a bigger
image. There are several methods for template matching such as Naive template matching,
image correlation matching and sum of absolute differences [54]. In image correlation
matching, the position of the given pattern is determined by a pixel wise comparison of the
image with the template that contains the desired pattern. To calculate this comparison,
normalized cross correlation is a reasonable choice. Normalized cross correlation (NCC)
is calculated between the template and the original thumbnail image [55], the amount is

25

between -1 and 1 which 1 means the two images are identical and -1 means one image
negates the other image and finally 0 means the two images are not correlated at all. In this
method the maximum correlation coefficient is at the starting point of the template. Figure
12 shows the rotated image and the detected hashmark.

Figure 12. Rotated image(left) and the template (right)

After the hashmarks are detected, then the coordinates of their corresponding
corners are used to calculate the transform matrix and then to align the rotated
image(source) to the original one(target). Figures 13-15 show the original thumbnail
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image, the rotated thumbnail image and the rotated image registered to the original image
respectively.

Fig13. Original thumbnail image
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Fig14. Rotated thumbnail image
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Fig15.Rotated thumbnail image registered to the original thumbnail image
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3.2. Image registration in WSI immunofluorescence images
We previously described a method for registration of two thumbnail whole slide
images using the coordination of the artificial landmarks. However, a thumbnail image is
a low-resolution image that gives only an overview of the high-resolution image. What we
have, is a set of immunofluorescence images that need to be registered. Therefore, we
developed automatic feature-based registration techniques which extract naturally
occurring features from the images rather than rely on artificially created features.
Analysis of the sequentially scanned whole slide images showed that the
differences between slides did not include non-rigid deformation from one slide to the
other. The differences between sequential images involved changes in intensity, rigid
translation, and possibly rotation. Therefore, we developed schemes based on intensity,
and on features extracted from the images. The result of intensity-based registration is
shown in Figure16.
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Figure 16. Intensity based registration result

Figure 17. Feature based registration result
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To be able to implement feature-based registration, first the features of interest
(lines, points, ...) need to be extracted. Even though there are no perfectly circular shapes
in the whole slide images, by applying the Hough Transform and limiting the radius of the
circles we can identify roughly circular regions of the images which can be used to generate
features for the registration process. An example is shown in Figure 18 where the circular
regions identified are shown as green circles. The centers of these circles were then used
as points of interest for feature-based registration.

Fig.18 Hough Transform result

The second method used for extracting key points to be used for feature-based
registration made use of the regionprops algorithm which finds the centroids and areas of
contiguous blobs in an image. The whole side image was binarized as shown in Figure 19.
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Figure 19. Binarized Image

The binarized image was processed using morphological operations of dilation and
erosion. The result is shown in Figure 20. The process results in the filling of “holes” in
the image and filtering out some of the noise, resulting in isolated connected regions.

Figure 20. Binarized image after morphological processing
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Fig 21. Inverted Image of the processed Binary Image

If we now take an inverse of this processed image as shown in Figure 21, and then
take the intersection of the inverted image and the original binarized image we obtain the
image shown in Figure 22 that contains only the connected components (blobs) generated
by the processing operation.

Figure 22. Intersection of the inverse of the morphologically processed image from Figure 21 and the
original binarized image from Figure 19
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The centroids and areas of the connected components are found, and the three
connected components with the largest areas are selected. The centroids of these areas,
shown by crosses in Figure 23 are used as features for constructing the affine matrix which
is used for registering the images.

Figure 23. Extracted points for Feature based Image registration are marked

After the registration was completed, color thresholding was used to separate out
the regions in the image that had taken up the different antibodies. Recall that the
antibodies fluoresce at different colors. An example of an image with two different
antibodies is shown in Figure 24. We can view each colored region as a cell or a set of cells
that have taken up a particular antibody.
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Figure 24. Example of an image with fluorescent labels green and red for two different antibodies.

The following image shows the results of the color thresholding algorithm to obtain
the location of the cells which have taken up the antibody labeled with the green fluorescent
label.

Figure 25. Color thresholding result for the antibody labeled with a green fluorescent label
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Each location which takes up a particular antibody is treated as an object and
statistics for each object are collected for further analysis.

The statistics include the

centroid of the objects, their major axis length, minor axis length, the area of every object,
which is simply number of pixels for that object, and the perimeter of the object. A sample
of this data is presented in Table 1. Note that we also know the coordinates of each of
these objects.

Area

Centroid(x) Centroid(y) Major Axis Length

Minor Axis Length

Perimeter

25

563.44

308.92

6.908159097

4.773259323

15.341

9

593

617

3.464101615

3.464101615

7.476

15

597.6

664.6

4.760952286

4.188874153

10.751

16

599.5

178

5.977883203

3.596050484

11.884

18

601.666667

84.8333333

5.777885617

4.210362088

12.62

12

619.5

422

4.618802154

3.464101615

9.436

59

624.79661

484.254237

11.82523465

7.344929342

30.318

21

655.571429

40.7142857

6.595402825

4.261516809

13.935

147

665.959184

800.843537

14.75115672

13.07430351

43.253

81

676.753086

144.037037

16.18902405

7.008253874

36.769

99

677.121212

480.575758

12.34046587

10.38219809

33.147

65

676.784615

533.076923

10.16041851

8.579686703

27.151

55

678.054545

307.745455

9.641168609

7.530137069

24.314

18

692

423.5

8

3.464101615

15.622

131

696.992366

735.496183

15.35785436

11.50872129

42.955

9

696

415

3.464101615

3.464101615

7.476

9

697

426

3.464101615

3.464101615

7.476

26

723.615385

7.19230769

7.889735877

4.393894448

16.54

177

731.768362

600.237288

18.2798396

12.85635299

49.414

23

748.869565

254.695652

8.061365453

3.902710368

15.895

12

751.5

240

4.618802154

3.464101615

9.436

78

760.051282

132.974359

12.78769674

8.146835774

30.583

93

784.021505

396.516129

13.57905079

9.05811407

34.048

85

824.576471

448.505882

12.73504546

8.791204916

32.667

65

824.676923

513.907692

11.78267174

7.232278057

27.589

120

832.766667

280.666667

16.35715314

9.53212038

39.027

55

842.490909

179.509091

10.71159917

7.555746268

27.407

77

846.506494

553.181818

15.70405159

7.41622206

38.737

73

853.945205

73.1643836

10.95886725

8.733915833

28.35

47

853.93617

473.702128

9.935543994

7.061943978

25.356

133

858.984962

745.210526

15.88983429

10.82156048

39.862

30

859

626.5

6.92820323

5.773502692

17.276

83

869.650602

620.313253

10.89124318

10.04298462

31.236

81

872.17284

657.271605

11.52393507

9.203321707

30.285

40

896

168.575

9.725854469

5.584301345

21.709

98

924.479592

363.091837

13.83665372

9.234508886

34.164

31

923.580645

609.612903

9.587529376

5.27800052

21.593

23

924.391304

321.565217

6.766533631

4.502862906

14.671

29

928

120.551724

10.24975469

4.174740493

20.212

159

932.201258

907.138365

21.86372059

12.42707264

66.31

9

928

127

3.464101615

3.464101615

7.476

37

Table 1. A part of the calculated statistics for the green dots after applying the color thresholding algorithm
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Speed Up Robust Features (SURF) is another approach in finding and matching
features that are locally distinct points in an image to register WSI immunofluorescence
images. The original algorithm used for key point detection is called SIFT (Scale Invariant
Feature Transform). SURF is mainly inspired by SIFT but is several times faster than SIFT.
One of the most critical advantages of SIFT features is that they are not affected by the
scale or the orientation of the image. In SIFT algorithm, first, in order to reduce the noise,
the image is blurred using Gaussian Blurring methods. By applying Gaussian Blur, minor
details are removed from the image, and only information such as the shape and edges are
remained. Then several scales of the original image are generated and later are blurred by
Gaussian blur. In the next step Difference of Gaussian (DoG) is calculated such that one
blurred image of the original image is subtracted from another less blurred version of the
original image. In the next step, the key points are localized; the local maxima and minima
are found, and later low contrast key points are removed. In order to find local maxima and
minima, every pixel in the image is compared with its neighboring pixels and is selected
as a key point if its value is the highest or the lowest among its neighbors. Now that the
potential key points haveDesktopDe been specified, a final check is essential to choose the
best key points; low contrast key points or those close to the edges are eliminated at this
point. Now that the robust key points have been selected, an orientation value to each key
point should be assigned so that the key point would be rotation invariant. For this purpose,
the gradients in x and y directions and later magnitude and orientation for each pixel are
calculated.
In the next step, for each key point, a histogram of the magnitude and orientation
for the neighboring pixels of that particular key point is created. The peak of the histogram
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would be the orientation of that key point. Finally, in the last step, using the neighboring
pixels, their orientations, and magnitude, for each key point, a descriptor which is the
representation of that specific point and contains the most important information about that
key point, is generated [56]-[57]. In order to register two or more images based on SURF
algorithm, first using SURF, features are extracted in both the reference and the source
images. Then, the transformation matrix between the two images is calculated, and finally,
the source image is registered to the reference image. Figures 26-30 show the original
images of Dapi 1 and Dapi 2, matching points of Dapi 1 and Dapi 2, and the registered
image, respectively.

Figure 26. Dapi1
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Figure 27. Dapi 2

Figure 28. Dapi1 matching points with Dapi 2
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Figure 29. Dapi 2 matching points with Dapi 1

Figure 30. Dapi 2 registered to Dapi 1
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In this chapter, we first registered two thumbnail images together based on fiducial
markers we detected, using template matching and other methods. Later, we registered
immunofluorescence whole slide images together using features in these images. For this
purpose, we extracted naturally occurring features in the reference and the source images
and then calculated the transformation to register the images together. The registration
compensates for moving the tissue slide inside the scanner and brings all the consecutive
images of each slide to the same coordinate system. In the next chapter, we will locate
multiple biomarkers (antibodies) for each cell and using the antibody vectors, we will
design our classifier to investigate the difference between primary and metastatic
pancreatic cancer cells.
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Chapter 4

Clustering and Classification
Unsupervised learning is a kind of learning that looks for a pattern in the dataset
with unlabeled data points. Clustering, which is one method of unsupervised learning, is
the grouping of data points into subgroups that share similar properties. This method is a
popular technique for statistical data analysis [58].
We deal with millions of pixels in only one sub image of a whole slide image. In
order to be able to apply machine learning supervised classification methods on the dataset,
unsupervised clustering methods could be an effective way to gain a general overview of
the dataset and see how many different classes there are in the dataset.
In this chapter, first using unsupervised clustering methods such as Vector
Quantization (VQ) and Principal Component Analysis (PCA), we investigate whether we
could cluster the cells into two different groups. This can provide insight about the data we
aim to classify ultimately. Later, we design two different classifiers based on
morphological features and antibody uptake, using Support Vector Machine (SVM) to
examine if we could classify pancreatic cancer cells into primary versus metastatic tumor
cells.
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4.1. Vector Quantization
To see if we could cluster cells into two categories with different characteristics,
we implemented one of the unsupervised clustering methods, LBG Vector Quantization
algorithm, on every patient in the dataset.
The preprocessing steps to prepare the images for both clustering methods,
including converting the images to binary, are described in the classification methods
section in detail. After completing the preprocessing steps, all the images are in binary
format, therefore the value of each pixel is either zero or one.

4.1.1. First Method Pixel-Based Vector Quantization
For the first method of pixel-based vector quantization, we started from the first
pixel in the first image. Note that the number of primary images is 26 for 26 different
antibodies, and the number of metastatic images is 26 for 26 different metastatic antibodies.
Each pixel has a coordinate of [x y z], the x and y are length and width coordinates of the
pixel in the image and z shows which among the 26 images this pixel is located in. For
instance, [150 1103 24] indicates that the pixel is in [150 1103] coordinate in the 24th
image. Starting from the first pixel in the first image, its value is either 0 or 1, which
demonstrates whether or not that specific antibody exists in the respective pixel. The
process continues onto the first pixel in the second image, coding it either 0 or 1, this goes
on until the 26rd image. So, for every pixel with an [x y] coordinate, there is now a vector
which contains zeros and ones for the absence or presence of antibodies, respectively. An
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example could be [1 1 1 0 0 1 1 1 1 0 1 0 0 0 1 1 0 0 1 1 0 0 1]. After preparing all the
primary images of a patient for VQ and completing the steps in order to have the primary
vectors of that patient, a need for the [x y] coordinates of each pixel was determined. , It
was possible at that juncture just to add the coordinates of each vector to the end of that
vector and make a matrix vector. Finally, all of these vectors were placed in a long matrix.

At this point, we implemented the Linde-Buzo-Gray (LBG) algorithm, which was
introduced by Yoseph Linde, Andrés Buzo and Robert M. Gray in 1980 as a vector
quantization algorithm. This method works quite similar to k-means clustering method, the
only difference being that the k-means algorithm works with points in each step but in
vector quantization it works with accumulated vectors in every step.
For this purpose, LBG vector quantization algorithm was implemented in
MATLAB. Additionally, the Python VQ built-in function was used to examine the
accuracy of this implemented VQ program. It was observed that both programs' results are
close to the same, but the Python VQ built-in function is faster than MATLAB.
All these vectors summed together and would be referred to as a centroid. y0 equals
this centroid, and y1 equals centroid plus another random vector. Considering that there
are two vectors, y0 and y1. The next steps were making up a matrix, going to each location,
taking the distance from y0, finding the ones that are closer to y0, and color-coding them
blue for proximity to y0 and red for proximity to y1. Then all points that belong to y0 were
averaged. This will be the new y0, then going to each location and taking the distance from
y0 and find the ones that are closer to new y0 again, the same process was replicated for
y1 too, until no changes were noted anymore [59]-[60].
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This VQ process was performed for all primary and metastatic directories. Figure
31 shows that by using an unsupervised clustering method such as vector quantization, no
specific pattern that shows any difference between two or more groups of cells was
discernible. In the next section, we unpack the second approach to vector quantization that
we attempted to see if the cells could be clustered unsupervised.

Figure 31. First model Pixel-based clustering using vector quantization

4.1.2. Second Method Pixel-Based Vector Quantization
Preprocessing steps for this part are the same as what had been done in the last part
termed first model pixel-based vector quantization. This time, in each image directory, one
of the nuclei images is considered as the reference image. The antibody images which are,
at that point, binarized, are added together and the summation is saved in the resulting
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image named sum image. In the reference nuclei image, different nuclei are labeled as
different objects. Due to their nature, cancerous cells do not have similar organized shapes,
and which has a probable effect on the number of objects and the labeling process.

Starting from the first pixel in sum image, if the pixel value is greater than or equal
to one, then an area equal to 50 by 50 pixels around that pixel but in the nuclei reference
image is searched in order to find nuclei and calculate the distance from the pixel in the
sum image to the found nuclei. The distances from the [x y] coordinates of that pixel to
each nucleus in that square are calculated, and the nucleus with the closest distance to that
particular pixel is found. In a matrix all non-zero pixels in sum image are associated with
a number that is the closest nucleus to that pixel. After this, the vectors associated to each
pixel in sum image, will be generated. The length of this vector equals to the number of
antibodies in the dataset; each element of this vector is either one or zero which shows the
presence or absence of each antibody in that specific pixel respectively. Later all these
vectors are concatenated in a long matrix and then all zero vectors are eliminated. After
clustering the pixels using vector quantization, all pixels in the same cluster are color
coding with the same color and different clusters are color coding with different colors.
Figure 32 shows the result for this quantization method. As it can be observed from the
result there is no discernable pattern that could distinguish between 2 clusters of cells.
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Figure 32. Second model Pixel-based clustering using vector quantization

4.1.3. Object-Based Vector Quantization
After the preprocessing steps, this time instead of investigating pixels for the
absence or presence of antibodies, we studied the cells. To see which antibodies were
associated with each cell, we found the center of each cell, then defined a vicinity of 50
pixels around the center and checked this circle around the center of every cell to see which
antibodies existed in this circle. We then defined a vector for each cell and for each
antibody that exists in the cell’s neighborhood, with the related element in the vector as 1
and the absence of each antibody as 0. We perform these steps for both primary and
metastatic antibodies of a patient, and subsequently perform vector quantization for each
one separately. The results are shown in Fig 33 to 40. It can be seen that there is not a
specific pattern to distinguish between two or more different classes.
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Figure 33. Object-based 2 clusters VQ for Liver Metastasis Patient 80

Figure 34. Object-based 3 clusters VQ for Liver Metastasis Patient 80
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Figure 35. Object-based 2 clusters VQ for Liver Metastasis Patient 105

Figure 36. Object-based 3 clusters VQ for Liver Metastasis Patient 105
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Figure 37. Object-based 2 clusters VQ for Liver Metastasis Patient 8

Figure 38. Object-based 3 clusters VQ for Liver Metastasis Patient 8

52

Figure 39. Object-based 2 clusters VQ for Liver Metastasis Patient 57

Figure 40. Object-based 3 clusters VQ for Liver Metastasis Patient 57
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4.2. PCA (Principal Component Analysis)
PCA or Principal Component Analysis is a technique to reduce the dimensionality
of high-dimensional data sets. In fact, PCA projects input data onto a lower-dimensional
subspace that still contains most of the information in the large set. It reduces the number
of columns while preserving as much information as it can. In PCA, the axes are ranked in
order of importance, with differences along the first principal component axis. The first
principal component gives the maximum variance, and each succeeding component
accounts for as much of the remaining variability as possible [61].

In this project, each variable belongs to a particular antibody, making it a 26
dimensions dataset. in order to look for any insight into the data, PCA is implemented to
make undertaking analysis a reasonable task.
Prior to applying PCA, the data had to be prepared first. The images were converted
to binaries, the different objects in the Dapi image were then labeled. The centroid of every
object was calculated. A surrounding window around the centroid of each object was
defined. Then in each antibody image, 26 in total, the coordinates of each object were
located, and the surrounding window was applied and searched for that particular antibody.
For each object, a vector was specified in which the presence of each antibody appeared as
1 and the absence of that antibody appeared as zero. Once all the vectors were calculated
for primary images of a patient, then all these steps were repeated for the metastatic images
of that particular patient. Next, all the primary vectors followed by metastatic vectors were
put in a long matrix. Finally, Principal component analysis was implemented in MATLAB.
Only for two patients, 80 and 105, was the primary and metastasis data fully available. In
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other patient cases, either primary or metastasis data exists in the dataset, but not both.
Therefore, in order to attempt PCA for other patients, primary data of one patient
concatenated to a metastasis data of another patient. Figures 41 to 43 show the result for a
few numbers of patients.

Figure 41. PCA result for Primary Metastasis data of patient 105, PCs 1 and 3
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Figure 42. PCA result for Metastasis data of patients 57 and 70, PCs 1 and 3
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Figure 43. PCA result for Primary data of patients 116 and 86, PCs 1 and 3

As it can be noticed from the results, in cases when the data is both primary or both
metastatic but from different patients, PCA could not cluster the data to two different
groups. However, when the dataset is primary-metastasis data from one patient, PCA has
clustered the data to almost two different clusters. Nevertheless, the results overlap in some
cases and this makes them not very reliable. Most of the variance is explained by PCs 1
and 3 -- the first and the third PCs.
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4.3. Classification Methods
In a classification problem which is a supervised method, a dataset is divided into
two classes for a binary classification or more for a multi-class classification, based on
specific features. Features are properties or characteristics of the data that are the same in
each class or sub population of a dataset [62]-[63]. Selecting proper features are extremely
important as they can reduce the dimensionality of the data, exclude present attributes in
the data and also help the classifier to make good predictions. Using a support vector
machine, we designed three approaches for classification to see if it were possible to
classify cells of a pancreatic cancer tissue into two classes of primary or metastasis using
immunofluorescence whole slide images of pancreatic tumors.

4.3.1. Support Vector Machine
Support vector machine (SVM) is a supervised machine learning method that
originally debuted in the 1990’s in the work of Vapnik and Chervonenkis. First, it was only
for linear classifying; however, later in 1992, Vapnik, Boser and Guyon suggested a way
to a non-linear classifier [64]. SVM is among the fastest classifiers which can be used in
two forms of linear and nonlinear. In the linear form, the classifier is able to divide the data
into two categories by a line, while in the non-linear form, the dataset cannot be separated
by a line and therefore other kinds of kernels such as Radial Basis Function (RBF) or
SIGMOID function are used. Linear SVM uses a hyperplane to divide the data into two
classes. This hyperplane is found such that to maximize the distance between the support
vectors which are the closest points to the hyperplane. Figure 44 represents the linear SVM
problem [65]. For cases in which the dataset is not easy to be separated linearly, the non-
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linear SVM works by mapping the dataset to a higher dimensional space where the data is
separable. Figure 45 [66].

Figure 44. Linear SVM [65]

Figure 45. mapping the dataset to a higher dimensional space [66]
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4.3.2. Dataset for the classification
Immunofluorescence whole slide images of both primary tumor (pancreas tumor)
and secondary tumor (either lung or liver) stained with different antibodies for patient 80
and 105 exist. For other patients, the information of either the primary tumor or the
secondary one exists. The dataset is very small, as the public datasets of cancers are mostly
brightfield microscopic images and the number of whole slide images are very limited and
mostly proprietary. Despite this challenge, we developed the model and tested it on our
small dataset.

4.3.3. Preparing the dataset for the classification
In order to prepare the images for two methods of classification in this project, i.e.
cell morphology classification and antibody uptake classification sub-method 1, we needed
to convert the color RGB images to binary. There are several methods for performing the
binarization, however, not all of them give acceptable results. In this project we tried
different methods for binarization such as OTSU Global thresholding, which is applied to
all pixels in an image and it is based on the histogram of the gray scale version of that
particular image [67]. If g(x,y) is the binarized image of f(x,y), the relation between g and
f is an equation (1). The other method for binarization is adaptive or local thresholding,

(1)
in which different thresholds are calculated for smaller parts of an image. With
examining several methods for binarization and evaluating the results, we determined that
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the best results were obtained by using the watershed segmentation algorithm. The idea of
Watershed segmentation which is a region-based approach comes from geography in which
a piece of land is divided into several small parts when it is flooded by rain. The watersheds
are in fact the lines that divide the land into several smaller parts. The original algorithm
of watershed segmentation was proposed by Digabel and Lantu´ejoul and improved by
Beucher and Lantu´ejoul [68]. The images are converted to binary using watershed
segmentation and the result for one image is presented in figure 47.

Figure 46. Patient 80 Primary Dapi
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Figure 47. (Watershed Segmentation) for separating the cells (Patient 80 Primary Dapi)

The images are now preprocessed. Altogether, there are 26 antibodies in the
different images of primary and metastatic tumors. The list of antibodies are as follows:
Bdac1, ccr3, cd103, cd11b, cd141, cd163, cd19, cd31, cd4, cd54ra, cd56, cd621,
cd8, epcam, foxp3, gfap, gzmb, il10, il17, ki67, lox1, mct, mpo, muc1, prg2, sma
For shaping the classification problem and solving that, two types of features are
extracted from the immunofluorescence whole slide images of pancreatic cancer of the
patients in the dataset. The first type of features is based on the uptake of each cell of
different antibodies in the primary and metastatic tumors. The second type of features is
based on morphology of the cells including area, perimeter, etc. The three methods of
classifying the cells are presented in the following sections.

4.4. Different methods of classification using SVM
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4.4.1. Classification based on antibody uptake in binary images
In this method, after converting the RGB images of the cells (dapi) and the
antibodies to binary, with each antibody in a different fluorescent image--, we found the
center of each cell and defined a vicinity of 50 pixels around the center to check this circle
around the center of every cell to see which antibodies exist in this circle. Then we define
a vector for each cell. For each antibody that exists in the cell’s neighborhood, the related
element in the vector was given a 1; while in the absence of each antibody the element in
the vector would be given a 0. These steps were performed for both primary and metastatic
antibodies of all patients. Therefore, for each cell there will be a vector of 26 elements
which these elements would be either zero or one. In the end, there will be a matrix with
all primary tumor vectors followed by all metastatic tumor vectors.
The primary cells are labeled as class 1 (C1) and the metastatic tumor cells are
labeled as class 2 (C2). This long matrix would be fed to SVM. An example of the data
that is fed to this model is presented in the following table.
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Primary
tumor
cells(object
s)

Metastatic
tumor
cells(object
s)

Antibody
1
Objec 0
t1
Objec 1
t2
Objec 0
t3
...
Objec 1
t
1350
Objec 0
t
1351
Antibody
1
Objec 1
t1
Objec 0
t2
Objec 0
t3
…
Objec 1
t
1795
Objec 1
t
1796

Antibody
2
1

Antibody
3
1

…

Antibody2 Clas
6
s
… 0 0 1 1
C1

0

1

… 0 1 1 0

C1

0

0

… 0 1 1 0

C1

…
1

1

1 1 0 1

C1
C1

1

0

… 1 0 0 0

C1

Antibody
2
1

Antibody
3
1

…

0

0

… 1 1 1 1

C2

0

0

… 1 1 1 0

C2

Antibody2
6
… 1 0 0 0
C2

1

0

… 1 1 0 0

C2
C2

1

1

… 0 0 1 1

C2

Table 2. Classification- Antibody uptake in binary images for patient 105

4.4.2. Classification based on antibody uptake in grayscale images
In this method, only the images of the cells (dapi) are binarized. The antibody
images are converted to grayscale images and then the intensities are normalized. When
searching the vicinity of 50 pixels around each cell for existing antibodies, the normalized
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amount of the intensity of the antibody is put in the related element in the antibody vector
instead of just a numerical one. So, for each cell, there will be a vector of 26 elements. At
the end, there would be a matrix with all vectors of primary tumor antibodies followed by
all vectors of metastatic tumor antibodies. The primary cells are labeled as class 1 (C1) and
the metastatic tumor cells are labeled as class 2 (C2). This file is fed to SVM. An example
of this model is presented in the following table.

Primary
tumor
cells(obje
cts)

Metastati
c
tumor
cells(obje
cts)

Object 1

Antibo
dy1
0.07

Antibody Antibody …
2
3
0.2
0.02
… 0.
0
5

Object 2

0.0016

0

0

… 0

Object 3
...
Object
1350
Object
1351

0.01

0.003

0

0.045

0.0005

0.0032

… 0
…
0

0.014

0.012

0

… 0

Antibo
dy1
0.022
0.0013
0.0019

Antibody
2
0.0014
0.044
0

Antibody
3
0.013
0.065
0.0061

…

0

0.006

0.0012

0

Object 1
Object 2
Object 3
…
Object
1795
Object
1796

0.
0
0
3
0.
0
6
0

Antibody2
6
0.019

Class

0.0003

C1

0.005

C1

0

0.033

C1
C1
C1

0

0.055

C1

… 0
… 0
… 0

0
0
0

Antibody2
6
0.0067
0.0018
0.009

0.018

… 0

0

0.0444

C2
C2
C2
C2
C2

0

… 0

0

0.0017

C2

Table 3. Classification- Antibody uptake in grayscale images for patient 105
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4.4.3. Classification based on Morphological features
The second type of features is based on morphology of the cells. Morphological
image processing are non-linear operations related to the shapes of objects in the images.
The purpose of this part is to investigate if based on the morphology of the cells the
classifier could differentiate between primary and metastatic tumor cells. An example of
this model is presented in the following table.

Primar
y tumor
cells(obj Object 1
ects)
Object 2
Object 3
...
Object
1350
Object
1351
Metasta
tic
tumor
Object 1
cells(obj Object 2
ects)
Object 3
…
Object
1795
Object
1796

Area

Perimeter Solidity

…

42

25.16

0.5368

…

32

25.67

0.8421

…

…

…

…

…
…

…

…

…

11

8.79

1

Area

Perimeter Solidity

…

20
8
…

14.6
13.72
…

0.73
0.99
…

…
…
…

…

…

…

18

14.2

0.89

0.0 0.0
5
03
… 0.0
6
… …

Eccentricit
y
0.5873

Class

0.9409

C1

…

C1

…

…

…

C1
C1
C1

…

…

0.6847

C1

…
…
…

…
…
…

Eccentricit
y
0.86
1
…

…

…

…

…

C2
C2
C2
C2
C2

…

…

…

1

C2

…

Table 4. Classification-Morphology features for patient 105
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4.5. Results of the Classification
4.5.1. Classification- Antibody uptake in binary images
In this case, the highest accuracy reached was 82%. The classifier was trained with
the primary and metastatic information of a patient and then tested with the information of
another patient. In this method, the antibody vectors that have been generated for primary
and metastatic tumor cells specify the information about presence or absence of the
antibodies and inform whether or not they belong to the cell. In fact, metastatic tumor cells
are just primary tumor cells that immigrate through the blood or lymph systems to other
places in the body. There is no typological difference in between primary tumor cells and
metastatic tumor cells [69] only a differing amount of protein expression in some cases.
Therefore, putting one for the presence of the antibody in the vicinity of the cell
and putting zero for the absence of the antibody does not clarify if the protein expression
of a specific antibody is different for primary versus secondary tumor cells.

In this method, the classifier classified the cells(objects) mostly correctly when the
borders of the cells were clearly specified, and the cells were separate. Therefore, this
classifier works under the circumstance of clear borders for nuclei. Figure 48 to 50 show
the results for metastatic tumor of patients 86, 105 and 8, respectively. The blue objects are
the cells that have been classified correctly.
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Figure 48. Metastatic tumor patient 86, blue cells have been classified correctly and red cells have been
classified wrongly

Figure 49. Metastatic tumor patient 105, blue cells have been classified correctly and red cells have been
classified wrongly
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Figure 50. Metastatic tumor patient 8, blue cells have been classified correctly and red cells have been
classified wrongly

4.5.2. Classification-Morphological features
In this model, morphological features of the cells were extracted to be used in the
SVM classifier. Our desire was to see if primary and secondary tumor cells were different
in shape. The features that are used here are as follows:
Area: Actual number of pixels in the object.
Major Axis Length and Minor Axis Length: Length of the major axis and minor
axis of the ellipse, respectively.
Eccentricity: Eccentricity which its value is between zero and one is the measure
of how nearly circular the ellipse is.
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Solidity: area of an object divided by the area of its convex hull.
Perimeter: Distance around the boundary of an object.
Elongation: Elongation is the ratio between the length and width of the smallest
rectangle containing the object in an image [70]-[71].
Several other morphology features such as circularity, extrema and etc. have been
calculated and fed to the classifier to compare the results. The highest accuracy achieved
in this method was 70%. It was observed that primary and secondary tumor cells are not
that different in morphological aspects. This was expected, as the secondary cells are
actually just primary cancer cells that break away from the primary tumor where they
originated and travel via blood or lymph system to another organ to form a secondary tumor
[72].

4.5.3. Classification- Antibody uptake in grayscale images
In this method, most cases (a case is defined, for example, when the classifier is
trained based on the information of one patient and then tested with the information of
another patient) achieved an accuracy of 90 % or higher. This method consisted of the
normalized intensity related to the amount of protein expressions of different antibodies in
primary and metastatic tumor cells being fed to the classifier.
The reason that accuracy in this method -- using normalized intensity of antibody
uptake in grayscale images -- was much higher than the other methods is that primary and
metastatic tumor cells are mostly the same in terms of morphology and antibody uptake,
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but have an observable difference in their amount of protein expression.
Immunofluorescence images are very sensitive and are therefore very suitable to be used
to discern and compare how primary and secondary cells are different in the expression of
their proteins. Even still, when the amount of protein is very low, the cells with low protein
expression might be hidden behind the cells with high protein expression, in general with
fluorescent images, the amount of signal in a cell has a linear relationship with the amount
of protein expression in that cell.
Table 5 presents the information of the patients whose data has been used in the
training and testing of the classifier. For instance, PM 80 in the Train column signifies that
primary and metastatic tumor information of patient 80 has been used to train the classifier.
Similarly, P116-M8 in the Test column means that the primary information of patient
number 116 and the metastasis information of patient number 8 have been used to test the
model. The 4 metrics, which include accuracy, precision, recall and f1 score, have been
used to evaluate the performance of this classifier. The definition of these metrics and their
formulas - with abbreviations TP, TN, FP and FN for True Positive, True Negative, False
Positive and False Negative, respectively - are as follows: [73]
Accuracy: Number of correct predictions divided by total number of predictions
Accuracy = TP+TN/TP+FP+FN+TN
Precision: True positive divided by total number of true positive and false positive
Precision = TP/TP+FP
Recall: True positive divided by total number of true positive and false negative
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Recall = TP/TP+FN
F1 score: 2 times precision multiply by recall divided by total number of precision
and recall
F1 Score = 2*(Recall * Precision) / (Recall + Precision)
Though accuracy is very important in the assessment of the performance of a
classifier, other metrics represent other significant aspects of that classifier as well. For
instance, high precision implies a low false positive rate.
The highest accuracy in this method was 96 %. The other metrics confirmed the
good performance of this classifier. Exceptions to this accuracy occurred for patients such
as patient 116 for whom the Dapi stained scan of the cells was extremely low in intensity
for the whole image and for patients for whom the metastasis information was not available
in the dataset. In instances of the latter, the primary information of the patient had to be
combined with the metastasis information of another patient in order to contribute to the
classifier, therefore, the accuracy was not very high. Other than these two exceptions, the
performance of the designed classifier was high. Nevertheless, this model should be
examined in a larger dataset.
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Train
PM 80
PM 80
PM 80
PM 105
PM 105
PM 105
PM 105
PM 105

Test
PM 105
P116-M8
P105-ML8
PM 80
P116-M8
P80-M70
P80-M10
P80-ML8

Accuracy
96 %
65%
91 %
94 %
70%
92 %
93%
93%

precision
0.72
0.67
0.91
1.00
0.78
1.00
0.98
1.00

recall
1.00
0.96
1.00
0.88
0.77
0.88
0.88
0.88

f1-score
0.84
0.79
0.95
0.94
0.78
094
0.93
0.94

Table 5. Metrics for different cases in the classification

As we noticed from the results, PCA could cluster the data into two different
groups. in cases when the primary or metastatic data is both from the same patient, not
different patients. Most of the variance is explained by PCs 1 and 3 -- the first and the third
PCs. Using Vector Quantization, though, there is no discernable pattern to cluster the data
to two or more different groups.
In supervised methods, we designed two types of classifiers; the first one was based
on the morphological characteristics of primary versus metastatic tumor cells with the
highest accuracy of 70%. We noticed that morphological features are not proper choices
for distinguishing between primary and metastatic tumor cells, as the secondary cells are
actually just primary cancer cells that break away from the primary tumor where they
originated and travel via blood or lymph system to another organ to form a secondary
tumor.
Our approach for designing the second type of the classifier was based on multiple
antibodies uptake in the primary versus metastatic tumor cells. For this purpose, we first
examined the presence of different antibodies in a cell and later the amount of protein
expressions in different antibodies. We achieved the accuracy of 90% and higher in this
method and the reason is that primary and metastatic tumor cells are mostly the same in

73

terms of morphology and antibody uptake, but have an observable difference in their
amount of protein expression. Also, , in general with fluorescent images, the amount of
signal in a cell has a linear relationship with the amount of protein expression in that cell
and this makes this kind of image a good choice for detecting the amount of a specific
antibody or a panel of different antibodies to be used in further analysis.
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Chapter 5

Summary, Conclusions and, Future Work
The high mortality rate of pancreatic cancer and its poor response to common
cancer treatments such as radiotherapy, immunotherapy, and chemotherapy have fueled
research to develop novel therapeutic approaches for the diagnosis, treatment, and possibly
cure of this highly lethal disease.

Tumor associated biomarkers are currently being intensively studied and have
shown encouraging results for the management of pancreatic cancers. However, metastasis
which is responsible for about 90 % of cancer deaths, is poorly understood. Understanding
the biology and the dynamic of metastasis is crucial in the discovery and development of
innovative therapies for this challenging cancer. Comparison of the absence or presence of
validated biomarkers in primary versus secondary tumor sites can bring an insight into how
the two tumors are different despite being originated from the same organ, and this can in
turn help with revising the available or developing new treatment methods.

In this project, our ultimate goal was to design a classifier to classify pancreatic
tumor cells into two categories; primary or metastatic. Most of the literature deals with the
differences between normal cells and tumor cells and the classifiers are designed based on
these differences. We aimed to examine the differences between primary versus metastatic
tumor cells and investigate if the classifier could classify these cells based on two different
criteria; morphological feature and the uptake of different antibodies.
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For this purpose, after registering consecutive images of the same tissue slide
together, first we investigated whether using unsupervised clustering methods such as
Vector Quantization (VQ) and Principal Component Analysis (PCA) we could cluster
primary metastatic cells into two different groups.

We noticed from the results, in cases when the data is both primary or metastatic
but from different patients, PCA could not cluster the data into two different groups.
However, when the dataset is primary-metastasis data from one patient, PCA has clustered
the data to almost two different clusters. Nevertheless, the results overlap in some cases
and this makes them not very reliable. Most of the variance is explained by PCs 1 and 3 -the first and the third PCs.
In Vector Quantization, though, there is no specific pattern to distinguish between
two or more different groups.
In the classification methods, we designed two types of classifiers; the first one was
based on the morphological characteristics of primary versus metastatic tumor cells. In this
method, features such as area, perimeter, solidity, eccentricity etc. were analyzed to
examine if primary and metastatic tumor cells are morphologically different.
The highest accuracy achieved in this method was 70%. It was observed that
primary and secondary tumor cells are not that different in morphological aspects. This
was expected, as the secondary cells are actually just primary cancer cells that break away
from the primary tumor where they originated and travel via blood or lymph system to
another organ to form a secondary tumor.
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The second type of the classifier was based on antibody uptake in the primary
versus metastatic tumor cells. In this method, we first used the presence versus the absence
of the antibodies in the binary images of our dataset as features to be fed to the classifier
and later the normalized intensity related to the amount of protein expressions of different
antibodies in primary and metastatic tumor cells.
In the first method, the highest accuracy reached was 82%, however, in the second
method, most cases (a case is defined, for example, when the classifier is trained based on
the information of one patient and then tested with the information of another patient)
achieved an accuracy of 90 % or higher. This method consisted of the normalized intensity
related to the amount of protein expressions of different antibodies in primary and
metastatic tumor cells being fed to the classifier.
The reason that accuracy in this method -- using the normalized intensity of
antibody uptake in grayscale images -- was much higher than the other methods is that
primary and metastatic tumor cells are mostly the same in terms of morphology and
antibody uptake, but have an observable difference in their amount of protein expression.
Immunofluorescence whole slide images are highly sensitive and are therefore very
suitable to be used to discern and compare how primary and secondary cells are different
in the expression of their proteins. Even still, when the amount of protein is very low, the
cells with low protein expression might be hidden behind the cells with high protein
expression, in general with fluorescent images, the amount of signal in a cell has a linear
relationship with the amount of protein expression in that cell.
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Since the classifier is first trained based on the binary and later the grayscale images
of the antibodies of primary and metastatic pancreatic cancer tissues, the next step in this
work could be to investigate how the expression of a particular antibody or different panels
of antibodies are quantitatively different in primary versus metastatic tumor cells. Also,
since our dataset is considered a small dataset, further research will include examining the
performance of the designed classifier on a larger dataset.
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